Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: A prospective pilot study of women's treatment choices and medical and decision-analytic recommendations

Medical Decision Making

Volumn 20, Issue 3, 2000, Pages 251-262

  Unic, Ivana ^a   Verhoef, Lia C G ^a,b   Stalmeier, Peep F M ^a,c,d   Van Daal, Willem A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Arnhems Radiotherapeutisch Instituut   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Prophylactic mastectomy; Screening; Shared decision making; Time preferences; Utilities

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SCREENING; CONTROLLED STUDY; DECISION MAKING; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; PILOT STUDY; PROPHYLAXIS; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR;

EID: 0033927976     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X0002000301     Document Type: Article

References (44)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378: 789-92.
3. Eeles RA, Stratton MR, Goldgar DE, Easton DF. The genetics of familial breast cancer and their practical implications. Eur J Cancer. 1994;30A:1383-90
4. Easton DF, Ford D, Bishop DT, the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56:265-71.
5. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-8.
6. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol. 1991;14:451-4.
7. Pennisi VR, Capozzi A. Subcutaneous mastectomy: an interim report on 1,244 patients. Ann Plast Surg. 1984;12:340-7.
8. Riolo Nemecek J, Young L, Lopez MJ. Indications for prophylactic mastectomy. MO Med. 1993;90:136-40.
9. Houn F, Helzlsouer KJ, Friedman NB, Stefanek ME. The practice of prophylactic mastectomy: a survey of Maryland surgeons. Am J Public Health. 1995;85:801-5.
10. Bilimoria MM, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. Ca Cancer J Clin. 1995;45:263-78.
11. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 1995;24:412-9.
12. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA. 1997;277:997-1003.
13. Kerlikowske K, Grady D, Rubin SM, Sandrock C Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149-54.
14. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster VL. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA. 1996;276:33-38.
15. Ma L, Fishell E, Wright B, Hanna W, Boyd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst. 1992;84:781-5.
16. Geel AN van, Rutgers EJT, Vos-Deckers GC, de Vries J, Wobbes T. Vrouwen met erfelijk risico op borstkanker: consensus van chirurgische vertegenwoordigers van de werkgroepen voor erfelijke tumoren ten aanzien van intensieve controle, diagnostiek en preventieve ablatio. Ned Tijdschr Geneeskd. 1997;141:874-7.
17. McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982; 306:1259-62.
18. Holmes MM, Rovner DR, Rothert ML, et al. Women's and physicians' utilities for health outcomes in estrogen replacement therapy. J Gen Intern Med. 1987;2:178-82.
19. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Cummings BJ. Whose utilities for decision analysis. Med Decis Making. 1990;10:58-67.
20. Pauker SP, Pauker SG. The amniocentesis decision ten years of decision analytic experience. Birth Defects. 1987;3:151-69.
21. Verhoef LCG, Unie IJ, Stalmeier PFM, van Daal WAJ. Prophylactic mastectomy or screening for BRCAL/2 mutation carriers: a decision analysis using the tradeoffs of suspected carriers. Manuscript under review.
22. Allais M. The foundations of a positive theory of choice involving risk and criticism of the postulates and axioms of the American school. In: Allais M, Hagen O (eds). Expected Utility Hypothesis and the Allais Paradox. Dordrecht, The Netherlands: D. Reidel, 1979:27-145.
23. Ubel PA, Loewenstein G. The role of decision analysis in informed consent: choosing between intuition and systematicity. Soc Sci Med. 1997;44:647-56.
24. Von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. Princeton, NJ: Princeton University Press, 1944.
25. Savage LJ. The Foundations of Statistics. New York: Dover, 1954.
26. Samuelson PA. Probability, utility, and the independence axiom. Econometrica. 1952;20:670-8.
27. Coombs CH, Dawes RM, Tversky A. Mathematical Psychology: An Introduction. Englewood Cliffs, NJ: Prentice-Hall, 1970.
28. Unic I, Stalmeier PFM, Verhoef LCG, van Daal WAJ. Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer. Med Decis Making. 1998;18:268-77.
29. Stalmeier PFM, Unic IJ, Verhoef LCG, van Daal WAJ. Evaluation of a shared decision making program for women with suspected genetic predisposition for breast cancer: preliminary results. Medical Decis Making. 1999;19:230-41.
30. Froberg DG, Kane RL. Methodology for measuring health-state preferences. II: Scaling methods. J Clin Epidemiol. 1989;42:459-71.
31. McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med. 1981;305:982-7.
32. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med. 1978;299:1397-401.
33. Miyamoto JM, Eraker SA. Parameter estimates for a QALY utility model. Med Decis Making. 1985;5:191-213.
34. Verhoef LCG, Haan AFJ de, Daal WAJ van. Risk attitude in gambles with years of life: empirical support for prospect theory. Med Decis Making. 1994;14:194-200.
35. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston, MA: Butterworth, 1988.
36. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet. 1993;52:678-701.
37. Heckerling PS, Verp MS, Hadro TA. Preferences of pregnant women for amniocentesis or chorionic villus sampling for prenatal testing: comparison of patients' choices and those of a decision-analytic model. J Clin Epidemiol. 1994;47:1215-28.
38. Heckerling PS, Verp MS, Albert N. Patient or physician preferences for decision analysis: the prenatal genetic testing decision. Med Decis Making. 1999;19:66-77.
39. Elstein AS, Holzman GB, Ravitch MM, et al. Comparison of physicians' decisions regarding estrogen replacement therapy for menopausal women and decisions derived from a decision analytic model. Am J Med. 1986;80:246-58.
40. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med. 1978;299:1397-401.
41. Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Operations Research. 1980;28: 206-24.
42. Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. Science. 1997;275:1293-5.
43. Slovic P. The construction of preference. Am Psychologist. 1995;50:364-71.
44. Cohen BJ. Is expected utility theory normative for medical decision making? Med Decis Making. 1996;16:1-6.